论文部分内容阅读
在印度孟买,间日疟原虫引起的感染约占整个疟疾病例的80％。虽然该病的死亡率在下降,但由于复发引起的发病率仍然很高,伯氨喹是目前预防间日疟复发的唯一药物。在印度,预防间日疟复发的标准疗法是伯氨喹5天疗程。但是在1977年至1997年间,5日疗程的疗效从原来的约99％降至87％。为此作者采用世界卫生组织推荐的14天疗程与5天疗程作了比较研究。
In Mumbai, India, P. vivax-related infections account for about 80% of all cases of malaria. Although mortality from the disease is declining, primaquine is currently the only drug currently available to prevent the relapse of vivax malaria, due to the high incidence of recurrence. In India, the standard treatment for the prevention of vivax malaria relapse is a 5-day course of primaquine. However, the efficacy of the 5-day regimen was reduced from about 99% to 87% between 1977 and 1997. For this reason, the author used the World Health Organization recommended 14-day course of treatment and 5-day course of treatment were compared.